Research and Markets: Global Diabetic Retinopathy Epidemiology and Patient Flow Analysis 2015

<0> Research and Markets: Global Diabetic Retinopathy Epidemiology and Patient Flow Analysis 2015 </0>

<0> Research and MarketsLaura Wood, Senior ManagerFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

The report provides insights into Diabetic Retinopathy epidemiology, Diabetic Retinopathy diagnosed patients, and Diabetic Retinopathy treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Diabetic Retinopathy derived from epidemiological analysis, percentage of patients diagnosed with Diabetic Retinopathy, and percentage of patients treated with Diabetic Retinopathy therapy.

The study helps executives estimate Diabetic Retinopathy market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Diabetic Retinopathy prevalence, Diabetic Retinopathy diagnosis rate, and Diabetic Retinopathy treatment rate for the period 2014 - 2020. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan.

1. Diabetic Retinopathy: Disease Definition

2. Global Diabetic Retinopathy Patient Flow

3. Diabetic Retinopathy Patient Flow in the US

4. Diabetic Retinopathy Patient Flow in Europe

5. Diabetic Retinopathy Patient Flow in Germany

6. Diabetic Retinopathy Patient Flow in France

7. Diabetic Retinopathy Patient Flow in Spain

8. Diabetic Retinopathy Patient Flow in Italy

9. Diabetic Retinopathy Patient Flow in UK

10. Diabetic Retinopathy Patient Flow in Japan

11. Appendix

For more information visit

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.